Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas Read More

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data Read More

JAK2 inhibitors minimize disease while maintaining antitumor response Read More

The first one on the list of Moffitt's top research developments for 2017 is the FDA approval of CAR T therapy for certain aggressive types of adult lymphoma. Read More

New ZUMA-1 trial data published in The New England Journal of Medicine report long-term measurable remission rates 15 months following treatment with Yescarta™ Read More

Yescarta™ for Non-Hodgkin Lymphoma Launches Global Commercial Use for Breakthrough Immunotherapy Treatment Read More

CAR T therapy, a groundbreaking new treatment, utilizes the body’s own immune system to fight cancer. Read More

Dr. Frederick Locke, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, answers some frequently asked questions about CAR T cell therapy. Read More

Moffitt patients with an aggressive type of lymphoma were among the first to benefit in clinical trials of a groundbreaking therapy. Read More

The U.S. Congress has designated September as Blood Cancer Awareness Month. Moffitt Cancer Center is pleased to join in this effort as a way to educate the general public and provide support, strength and hope to individuals who are affected by blood cancer. Read More

Approximately every four minutes, someone in the United States is diagnosed with leukemia, lymphoma or another type of cancer that affects the blood cells, bone marrow or lymphatic system. Read More

Madison encourages other young adults with cancer to be fearless. Read More